EMERGENT BIOSOLUTIONS INC (EBS) — insider trading
Health Care · NYSE
EMERGENT BIOSOLUTIONS INC (EBS) has 26 reported SEC Form 4 insider transactions in our data, including 8 open-market sales among the most recent 26 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Williams Paul Anthony | Officer (SVP, Products Business) | Open-market sale | 3,000 | $8.40 | $25.2K | Form 4 |
| 2026-06-08 | Hartzel William | Officer (SVP, Bioservices) | Shares withheld for taxes / exercise cost | 1,741 | $8.00 | $13.9K | Form 4 |
| 2026-06-08 | Glessner Coleen | Officer (EVP, Quality & Ethics, and CPL) | Shares withheld for taxes / exercise cost | 2,018 | $8.00 | $16.1K | Form 4 |
| 2026-06-08 | LINDAHL RICHARD S | Officer (EVP, Chief Financial Officer) | Shares withheld for taxes / exercise cost | 3,964 | $8.00 | $31.7K | Form 4 |
| 2026-06-08 | Williams Paul Anthony | Officer (SVP, Products Business) | Shares withheld for taxes / exercise cost | 694 | $8.00 | $5.6K | Form 4 |
| 2026-05-01 | Zoon Kathryn C | Director | Open-market sale | 1,057 | $8.97 | $9.5K | Form 4 |
| 2026-05-01 | Zoon Kathryn C | Director | Open-market sale | 16,145 | $8.36 | $135.0K | Form 4 |
| 2026-05-01 | DeGolyer Donald W | Director | Open-market sale | 954 | $8.96 | $8.5K | Form 4 |
| 2026-05-01 | DeGolyer Donald W | Director | Open-market sale | 14,527 | $8.36 | $121.4K | Form 4 |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Open-market sale | 980 | $8.94 | $8.8K | Form 4 |
| 2026-05-01 | Dayal Sujata Tyagi | Director | Open-market sale | 12,781 | $8.36 | $106.8K | Form 4 |
| 2026-04-30 | Zoon Kathryn C | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Zoon Kathryn C | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Richard Ronald | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Richard Ronald | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | FOWLER JOHN D JR | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | FOWLER JOHN D JR | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | White Marvin L | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | White Marvin L | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Katkin Keith | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Katkin Keith | Director | Open-market sale | 15,481 | $8.28 | $128.2K | Form 4 |
| 2026-04-30 | Katkin Keith | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | DeGolyer Donald W | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | DeGolyer Donald W | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Dayal Sujata Tyagi | Director | Grant / award / vesting (derivative) | 11,296 | $0.00 | $0 | Form 4 |
| 2026-04-30 | Dayal Sujata Tyagi | Director | Grant / award / vesting | 25,344 | $0.00 | $0 | Form 4 |
Ask the chat about EBS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: EMERGENT BIOSOLUTIONS INC (EBS).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.